Sutro Biopharma (STRO) Total Current Liabilities (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Total Current Liabilities data on file, last reported at $75.1 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities fell 43.03% year-over-year to $75.1 million; the trailing twelve-month figure through Dec 2025 stood at $75.1 million (down 43.03% YoY), and the FY2025 full-year result was $75.1 million, down 43.03% from the prior year.
• Total Current Liabilities improved to $75.1 million in Q4 2025, from $71.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $133.0 million in Q1 2025 to a low of $22.7 million in Q1 2021.
• A 5-year average of $72.8 million and a median of $69.5 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities jumped 93.65% in 2024 and sank 45.24% in 2025, its largest moves.
• Tracing STRO's Total Current Liabilities over 5 years: stood at $41.7 million in 2021, then jumped by 59.45% to $66.5 million in 2022, then surged by 40.87% to $93.7 million in 2023, then soared by 40.69% to $131.9 million in 2024, then tumbled by 43.03% to $75.1 million in 2025.
• Business Quant data shows STRO's Total Current Liabilities at $75.1 million in Q4 2025, $71.9 million in Q3 2025, and $74.2 million in Q2 2025.